. "In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged"@en . . . . . . . . . . . . . . "69712-56-7"@en . . . "Cefotetan is 88% plasma protein bound."@en . "No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations."@en . . . "The bactericidal action of cefotetan results from inhibition of cell wall synthesis by binding and inhibiting the bacterial penicillin binding proteins which help in the cell wall biosynthesis."@en . . . . . . . . . "(6R,7S)-7-(4-(Carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid"@en . "* 10.4 L [elderly patients (greater than 65 years) with normal renal function] * 10.3 L [healthy volunteers (aged 25 to 28 years)]"@en . "A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. [PubChem]"@en . . . . . "For prophylaxis and treatment of bacterial infections."@en . . "Avoid alcohol as it can cause a disulfiram effect."@en . "Cefotetanum"@en . "Cefotetan"@en . . . . "Enteric bacteria and other eubacteria"@en . . . . . . . . . . . "* 1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)] * 1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)]"@en . . . "Maurizio Zenoni, \"Process for obtaining compounds usable in the production of Cefotetan, and new compounds obtained thereby.\" U.S. Patent US20020169327, issued November 14, 2002."@en . " "@en . . . "approved"@en . . . . .